Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Sequential mutational evaluation of CALR -mutated myeloproliferative neoplasms with thrombocytosis reveals an association between CALR allele burden evolution and disease progression.

Cottin L, Riou J, Orvain C, Ianotto JC, Boyer F, Renard M, Truchan-Graczyk M, Murati A, Jouanneau-Courville R, Allangba O, Mansier O, Burroni B, Rousselet MC, Quintin-Roué I, Martin A, Sadot-Lebouvier S, Delneste Y, Chrétien JM, Hunault-Berger M, Blanchet O, Lippert E, Ugo V, Luque Paz D.

Br J Haematol. 2019 Nov 11. doi: 10.1111/bjh.16276. [Epub ahead of print]

PMID:
31710700
2.

The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort.

Damotte D, Warren S, Arrondeau J, Boudou-Rouquette P, Mansuet-Lupo A, Biton J, Ouakrim H, Alifano M, Gervais C, Bellesoeur A, Kramkimel N, Tlemsani C, Burroni B, Duche A, Letourneur F, Si H, Halpin R, Creasy T, Herbst R, Ren X, Morel P, Cesano A, Goldwasser F, Leroy K.

J Transl Med. 2019 Nov 4;17(1):357. doi: 10.1186/s12967-019-2100-3.

3.

Paraneoplastic hyperleukocytosis mimicking hematologic malignancy revealing a localized lung cancer.

Marouf A, Chapuis N, Alary AS, Burroni B, Kosmider O, Alifano M, Bouscary D.

Ann Thorac Surg. 2019 Aug 10. pii: S0003-4975(19)31164-6. doi: 10.1016/j.athoracsur.2019.06.064. [Epub ahead of print]

PMID:
31408646
4.

Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project.

Bailly C, Carlier T, Berriolo-Riedinger A, Casasnovas O, Gyan E, Meignan M, Moreau A, Burroni B, Djaileb L, Gressin R, Devillers A, Lamy T, Thieblemont C, Hermine O, Kraeber-Bodéré F, Le Gouill S, Bodet-Milin C.

Haematologica. 2019 Aug 1. pii: haematol.2019.223016. doi: 10.3324/haematol.2019.223016. [Epub ahead of print]

5.

T-cell large granular lymphocyte leukemia transfomation into aggressive T-cell lymphoma: a report of two cases with molecular characterization.

Belhadj M, Mansour D, Kaltenbach S, Deau-Fischer B, Franchi P, Tamburini J, Chapuis N, Damotte D, Kosmider O, Burroni B, Bouscary D.

Haematologica. 2019 Mar;104(3):e117-e120. doi: 10.3324/haematol.2018.205542. Epub 2018 Dec 20. No abstract available.

6.

Gray-zone Lymphoma Between cHL and Large B-Cell Lymphoma: A Histopathologic Series From the LYSA.

Sarkozy C, Copie-Bergman C, Damotte D, Ben-Neriah S, Burroni B, Cornillon J, Lemal R, Golfier C, Fabiani B, Chassagne-Clément C, Parrens M, Herbaux C, Xerri L, Bossard C, Laurent C, Cheminant M, Cartron G, Cabecadas J, Molina T, Salles G, Steidl C, Ghesquières H, Mottok A, Traverse-Glehen A.

Am J Surg Pathol. 2019 Mar;43(3):341-351. doi: 10.1097/PAS.0000000000001198.

PMID:
30540571
7.

Unusual location of a follicular lymphoma with features of pediatric-type follicular lymphoma.

Kanaan C, Burroni B.

Blood. 2018 Oct 18;132(16):1725. doi: 10.1182/blood-2018-07-862524. No abstract available.

PMID:
30337322
8.

CD13 expression in B cell malignancies is a hallmark of plasmacytic differentiation.

Raimbault A, Machherndl-Spandl S, Itzykson R, Clauser S, Chapuis N, Mathis S, Lauf J, Alary AS, Burroni B, Kosmider O, Fontenay M, Béné MC, Durrieu F, Bettelheim P, Bardet V.

Br J Haematol. 2019 Feb;184(4):625-633. doi: 10.1111/bjh.15584. Epub 2018 Sep 10.

PMID:
30198568
9.

Prognostic value of early 18F-FDG PET scanning evaluation in immunocompetent primary CNS lymphoma patients.

Birsen R, Blanc E, Willems L, Burroni B, Legoff M, Le Ray E, Pilorge S, Salah S, Quentin A, Deau B, Franchi P, Vignon M, Mabille L, Nguyen C, Kirova Y, Varlet P, Edjlali M, Dezamis E, Hoang-Xuan K, Soussain C, Houillier C, Damotte D, Pallud J, Bouscary D, Tamburini J.

Oncotarget. 2018 Mar 30;9(24):16822-16831. doi: 10.18632/oncotarget.24706. eCollection 2018 Mar 30.

10.

The role of radiotherapy as salvage and/or consolidation treatment in relapsed/refractory and high-risk diffuse large B-cell lymphoma.

Grignano E, Laurent J, Deau B, Burroni B, Bouscary D, Kirova YM.

Eur J Haematol. 2018 Apr 16. doi: 10.1111/ejh.13080. [Epub ahead of print]

PMID:
29660176
11.

Radiotherapy of relapse-refractory follicular lymphoma.

Grignano É, Deau-Fischer B, Loganadane G, Breton M, Burroni B, Bouscary D, Kirova YM.

Cancer Radiother. 2018 Apr;22(2):126-130. doi: 10.1016/j.canrad.2017.09.003. Epub 2018 Feb 22.

PMID:
29477304
12.

Efficacy and safety of high-dose etoposide cytarabine as consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary central nervous system lymphoma in immunocompetent patients.

Birsen R, Willems L, Pallud J, Blanc E, Burroni B, Legoff M, Le Ray E, Pilorge S, Deau B, Franchi P, Vignon M, Kirova Y, Edjlali M, Houillier C, Soussain C, Varlet P, Dezamis E, Damotte D, Bouscary D, Tamburini J.

Haematologica. 2018 Jul;103(7):e296-e299. doi: 10.3324/haematol.2017.185843. Epub 2018 Feb 22. No abstract available.

13.

Immune-related bone marrow failure following anti-PD1 therapy.

Michot JM, Vargaftig J, Leduc C, Quere G, Burroni B, Lazarovici J, Champiat S, Ribrag V, Lambotte O.

Eur J Cancer. 2017 Jul;80:1-4. doi: 10.1016/j.ejca.2017.04.004. Epub 2017 May 17. No abstract available.

PMID:
28527392
14.

Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.

Gravelle P, Burroni B, Péricart S, Rossi C, Bezombes C, Tosolini M, Damotte D, Brousset P, Fournié JJ, Laurent C.

Oncotarget. 2017 Jul 4;8(27):44960-44975. doi: 10.18632/oncotarget.16680. Review.

15.

[Immune-checkpoint and hemopathies].

Burroni B, Broudin C, Damotte D, Laurent C.

Ann Pathol. 2017 Feb;37(1):101-110. doi: 10.1016/j.annpat.2016.12.005. Epub 2017 Feb 1. Review. French.

PMID:
28161001
16.

Sarcoidosis occurring after lymphoma: report of 14 patients and review of the literature.

London J, Grados A, Fermé C, Charmillon A, Maurier F, Deau B, Crickx E, Brice P, Chapelon-Abric C, Haioun C, Burroni B, Alifano M, Le Jeunne C, Guillevin L, Costedoat-Chalumeau N, Schleinitz N, Mouthon L, Terrier B.

Medicine (Baltimore). 2014 Nov;93(21):e121. doi: 10.1097/MD.0000000000000121. Review.

17.

Systemic inflammation, nutritional status and tumor immune microenvironment determine outcome of resected non-small cell lung cancer.

Alifano M, Mansuet-Lupo A, Lococo F, Roche N, Bobbio A, Canny E, Schussler O, Dermine H, Régnard JF, Burroni B, Goc J, Biton J, Ouakrim H, Cremer I, Dieu-Nosjean MC, Damotte D.

PLoS One. 2014 Sep 19;9(9):e106914. doi: 10.1371/journal.pone.0106914. eCollection 2014.

18.

Desmoplastic fibroma of the ilium.

Rouchy RC, Courvoisier A, Wimsey S, Bourgeois E, Burroni B, Griffet J.

Int J Surg Case Rep. 2013;4(10):875-8. doi: 10.1016/j.ijscr.2013.06.016. Epub 2013 Jul 17.

19.

Recurrence of giant juvenile breast fibroadenoma in a girl with Turner's syndrome.

Calcaterra V, Coscia DR, Sgarell A, Burroni B, Podetta M, Andorno A, Ferrari A, Larizza D.

J Pediatr Endocrinol Metab. 2009 Mar;22(3):281-3.

PMID:
19492586
20.

[Experimental kidney transplantation: a comparison between different models].

Zonta S, Alessiani M, Abbiati F, Fayer F, Zitelli E, Bardone MC, Cobianchi I, Lovisetto F, Piccioni PF, Burroni B, Vigano J, Doni M, Dominioni T, Blangetti I, Lusona B, Morbini P, Dionigi P, Zonta A.

Minerva Chir. 2003 Oct;58(5):755-67. Italian.

PMID:
14603154
21.

Pharmacokinetic study of intraarterial local intestinal infusion of tacrolimus.

Alessiani M, Regazzi M, Abbiati F, Ferrari P, Molinaro M, Iacona I, Klersy C, Viezzoli A, Fayer F, Pileggi A, Zitelli E, Burroni B, Scandone M, Dionigi P, Zonta A.

Transplant Proc. 2000 Sep;32(6):1214-5. No abstract available.

PMID:
10995915

Supplemental Content

Loading ...
Support Center